-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fosciclopirox in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fosciclopirox in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fosciclopirox in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fosciclopirox in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fosciclopirox in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Fosciclopirox in Solid Tumor Drug Details: CPX-POM (Ciclopirox prodrug) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fosciclopirox in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fosciclopirox in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Fosciclopirox in Relapsed Acute Myeloid Leukemia Drug Details: CPX-POM (Ciclopirox prodrug)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fosciclopirox in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fosciclopirox in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Fosciclopirox in Refractory Acute Myeloid Leukemia Drug Details: CPX-POM (Ciclopirox prodrug)...
-
Company Profile
Ontex Group NV – Company Profile
Ontex Group NV (Ontex) is a provider of personal hygiene solutions. The company designs, develops, manufactures and markets disposable private label products for babies, women, and adults. The company’s product portfolio includes diapers, panty liners, baby pants, wet wipes, pads, pull-ups, belt diapers, shaped pads, under pads, tampons and rectangular pads. It markets products under various brands. The company offers its products to hospitals, nursing homes and pharmacies and also markets them to consumers directly. It operates distribution offices and...
Add to Basket -
Company Profile
Intersnack Group GmbH & Co KG – Company Profile
Intersnack Group GmbH & Co KG (Intersnack Group) produces and sells savory snacks. The company’s product portfolio includes potato chips, nuts, specialty snacks, and baked products. It also offers jumpys, ringli, donuts, fruit mixes, popcorn in various shapes and textures. Intersnack also provides roasted, coated and flavored nuts that include cashews, pista, and badam. The company also offers salted sticks and pretzels. It markets its products under various brands including Chio, Pom-Bar, Vico, funny-frisch, Bohemia, Kelly's, Ultje, Felix, Slovakia, Soletti,...
Add to Basket -
Product Insights
Alco Bio Fuel/ ArcelorMittal/ Electrabel/ Fluxys Belgium/ Ghent Port/ Mitsubishi/ Oiltanking/ PMV/ POM Oost Vlaanderen/ Proman – North-C-Hydrogen Plant – Flanders
Equip yourself with the essential tools needed to make informed and profitable decisions with our Alco Bio Fuel/ ArcelorMittal/ Electrabel/ Fluxys Belgium/ Ghent Port/ Mitsubishi/ Oiltanking/ PMV/ POM Oost Vlaanderen/ Proman - North-C-Hydrogen Plant - Flanders report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and...
-
Product Insights
POM Medical LLC, United States Revenue
GlobalData, the industry analysis specialist, has released its latest report: POM Medical LLC, United States Revenue. The medical devices sector is typified by frequent change and innovation in available devices, in response to demand from healthcare for ever more effective therapies and increased competition. As a result, the sector has seen the emergence of start-up medtech companies who are producing the most innovative and cutting-edge solutions to problems and issues faced by the healthcare industry. Most of these companies are...
-
Product Insights
Net Present Value Model: Hepsera
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Hepsera Drug Details Adefovir dipivoxil (Hepsera)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – fosciclopirox
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry fosciclopirox Drug Details CPX-POM (Ciclopirox prodrug) is under development for the treatment of advanced...